Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

295 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Increased CDA expression/activity in males contributes to decreased cytidine analog half-life and likely contributes to worse outcomes with 5-azacytidine or decitabine therapy.
Mahfouz RZ, Jankowska A, Ebrahem Q, Gu X, Visconte V, Tabarroki A, Terse P, Covey J, Chan K, Ling Y, Engelke KJ, Sekeres MA, Tiu R, Maciejewski J, Radivoyevitch T, Saunthararajah Y. Mahfouz RZ, et al. Among authors: jankowska a. Clin Cancer Res. 2013 Feb 15;19(4):938-48. doi: 10.1158/1078-0432.CCR-12-1722. Epub 2013 Jan 3. Clin Cancer Res. 2013. PMID: 23287564 Free PMC article.
A phase 2 trial of combination therapy with thalidomide, arsenic trioxide, dexamethasone, and ascorbic acid (TADA) in patients with overlap myelodysplastic/myeloproliferative neoplasms (MDS/MPN) or primary myelofibrosis (PMF).
Bejanyan N, Tiu RV, Raza A, Jankowska A, Kalaycio M, Advani A, Chan J, Saunthararajah Y, Mooney L, Maciejewski JP, Sekeres MA. Bejanyan N, et al. Among authors: jankowska a. Cancer. 2012 Aug 15;118(16):3968-76. doi: 10.1002/cncr.26741. Epub 2011 Dec 16. Cancer. 2012. PMID: 22180010 Free article. Clinical Trial.
Impact of molecular mutations on treatment response to DNMT inhibitors in myelodysplasia and related neoplasms.
Traina F, Visconte V, Elson P, Tabarroki A, Jankowska AM, Hasrouni E, Sugimoto Y, Szpurka H, Makishima H, O'Keefe CL, Sekeres MA, Advani AS, Kalaycio M, Copelan EA, Saunthararajah Y, Olalla Saad ST, Maciejewski JP, Tiu RV. Traina F, et al. Among authors: jankowska am. Leukemia. 2014 Jan;28(1):78-87. doi: 10.1038/leu.2013.269. Epub 2013 Sep 18. Leukemia. 2014. PMID: 24045501
Multiple mechanisms deregulate EZH2 and histone H3 lysine 27 epigenetic changes in myeloid malignancies.
Khan SN, Jankowska AM, Mahfouz R, Dunbar AJ, Sugimoto Y, Hosono N, Hu Z, Cheriyath V, Vatolin S, Przychodzen B, Reu FJ, Saunthararajah Y, O'Keefe C, Sekeres MA, List AF, Moliterno AR, McDevitt MA, Maciejewski JP, Makishima H. Khan SN, et al. Among authors: jankowska am. Leukemia. 2013 Jun;27(6):1301-9. doi: 10.1038/leu.2013.80. Epub 2013 Mar 14. Leukemia. 2013. PMID: 23486531
Novel homo- and hemizygous mutations in EZH2 in myeloid malignancies.
Makishima H, Jankowska AM, Tiu RV, Szpurka H, Sugimoto Y, Hu Z, Saunthararajah Y, Guinta K, Keddache MA, Putnam P, Sekeres MA, Moliterno AR, List AF, McDevitt MA, Maciejewski JP. Makishima H, et al. Among authors: jankowska am. Leukemia. 2010 Oct;24(10):1799-804. doi: 10.1038/leu.2010.167. Epub 2010 Aug 19. Leukemia. 2010. PMID: 20724984 No abstract available.
295 results